SIMULTANEOUS METHOD FOR THE ESTIMATION OF BEDAQUILINE AND DELAMANID IN HUMAN PLASMA USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
Keywords:Bedaquiline, Delamanid, Plasma, HPLC
Objective: A specific, simple and sensitive high-performance liquid chromatographic method for the estimation of Bedaquiline (BDQ) and Delamanid (DLM) in human plasma was developed.
Methods: The method involved deproteinization and further extracted the analyte using Solid Phase Extraction (SPE) cartridge and analysed using C18 column with the wavelength set at 231 nm. The isocratic mobile phase consisted of 10 mmol ammonium acetate buffer containing 0.25% acetic acid and 0.02% trifluoroacetic acid and acetonitrile in the ratio of 20:80(v/v). The validation parameters were evaluated. The method was applied to estimate plasma BDQ and DLM collected from five MDR-TB patients.
Results: Well resolved peaks of BDQ and DLM at retention times of 5.4 and 2.6 min were obtained respectively. The calibration curve was linear over a range of 0.01–10.0 µg/ml for both BDQ and DLM. The intra-and inter-day relative standard deviations for standards were below 10%. The recoveries for BDQ ranged from 101% to 107% and 98% to 107 % for DLM respectively.
Conclusion: A specific and sensitive method for simultaneous determination of BDQ and DLM in plasma using high-performance liquid chromatography was developed. This method can be used in clinical studies to evaluate drug exposure.
Matsumoto M, Hashizume H, Tomishige T, Masanori K, Hidetsugu T, Hirofumi S, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;11:e466.
Cuyckens F, Balcaen LIL, De Wolf K, De Samber B, Van Looveren C, Hurkmans R, et al. Use of the bromine isotope ratio in HPLC-ICP-MS and HPLC-ESI-MS analysis of a new drug in development. Anal Bioanal Chem 2008;390:1717–29.
Balcaen LIL, De Samber B, De Wolf K, Cuyckens F, Vanhaecke F. Hyphenation of reverse-phase HPLC and ICP-MS for metabolite profiling-application to a novel antituberculosis compound as a case study. Anal Bioanal Chem 2007;389:777–86.
Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831–5.
Kelly E Dooley, Jeong Gun Park, Susan Swindells, Reena Allen, David W Haas, Yoninah Cramer, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS clinical trials group study A5267. J Acquir Immune Defic Syndr 2012:59:455–62.
Jan Willem C Alffenaar, Mathieu Bolhuis, Kai Van Hateren, Marieke Sturkenboom, Onno Akkerman. Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2015;59:5675–80.
Meng M, Smith B, Johnston B, Carter S, Brisson J, Roth SE. Simultaneous quantitation of delamanid (OPC-67683) and its eight metabolites in human plasma using UHPLC-MS/MS. J Chromatogr B 2015;1002:78–91.
M Muller, H Stass, M Brunner, JG Muller, E Lackner, HG Eichler. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999;43:45.
Warner DF, Mizrahi V. Shortening treatment for tuberculosis–back to basics. New Engl J Med 2014;371:1642-4.